Clinical Trial: A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.

U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07318675) titled 'A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.' on Dec. 16, 2025.

Brief Summary: This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.

Study Start Date: Dec. 25, 2025

Study Type: INTERVENTIONAL

Condition: Actinic Keratosis (AK)

Intervention: DRUG: HW211026

Dose 1 and Dose 2

DRUG: Placebo

Dose 1 and Dose 2

Recruitment Status: RECRUITING

Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Disclaimer: ...